- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03473457
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)
The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Study Overview
Status
Intervention / Treatment
Detailed Description
Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease ,its' character is immature myeloid protocel abnormal differentiation and proliferation in the bone marrow. The disease is the most common type of adult acute leukemia, Overall survival (OS) was less than 50% in 5 years. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy.
CAR - T cells are taken in the form of genetic modification, and specific identified target antigen monoclonal antibody of single variable region (scFv) expression in T cell surface, and coupled with the activation of intracellular proliferation signal domain.When scFv recognizes antigens expressed in malignant cells, it stimulates the activation signal of downstream T cells and produces specific killing effects. CAR-T therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, although it start late, several clinical trials have been register in ClinicalTrials.gov.
The cluster of differentiation (CD) antigen serves as the target for identification and research in the immuno-phenotype detection of cells.As the surface markers of immune typing, CD molecules can be used as cell identification for expression types and levels on the cell surface.Cell surface of AML has a specific type of CD molecule expression,such as cluster of differentiation antigen 33(CD33),cluster of differentiation 38(CD38),cluster of differentiation 56 (CD56), cluster of differentiation 123(CD123), cluster of differentiation 117(CD117), cluster of differentiation 133(CD133), cluster of differentiation 34(CD34) and Mucl.Therefore, it provides some good targets for the immunotherapy of CAR T cells.In AML cells and mouse model,some studies have confirmed anti-CD33 CAR-T and anti-CD123 CAR-T with good similar lethality, but the toxicity of CAR-T to myeloid hematopoietic stem/progenitor cells and mononuclear cells is widespread.In comparison,CD123 CAR-T Off-target effects slighter than CD33 CAR-T.
In order to lay a foundation for the application of relapsed/refractory AML patients with CAR-T therapy,objects are refractory/ relapsed patients with AML,and plans to into the group of the number of cases in 50 cases.The main content is safety, efficacy and feasibility analysis of the CAR-T cells (single CAR-T or double CAR-T cells with CD33,CD38,CD56,CD123,CD117,CD133,CD34 or Mucl ) in the treatment of refractory/relapsed AML.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangdong, Guangdong, China, 510000
- Southern Medical University Zhujiang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Relapsed/Refractory AML patients
- Positive for any of CD33, CD38, CD56, CD117, CD123, CD34, or Muc1.(cytology, genetic testing)
- Estimated survival time is more than 3 months in multiple myeloma,and Karnofsky Performance Status(KPS) score is more than 80.
- No cytapheresis and cell separation contraindication.
- Hemoglobin is more than 80 gram per litre.
- The function of important organ was satisfied:(1)cardiac ultrasound indicated that cardiac ejection fractions is more than 50%(EF≥50%), and the electrocardiogram showed no obvious abnormality;(2)Blood oxygen saturation is more than 90%(SpO2≥90%);(3)Creatinine(Cr) is less than 2.5 times the upper limit of normal;(4)Alanine transaminase(ALT)and glutamic-oxalacetic transaminase(AST)is less than 3 times the upper limit of normal,and total bilirubin is less than 2 milligram per deciliter(TBil≤2.0mg/dL).
- After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk.
- Volunteered for this clinical trail and signed a consent form .
- Currently, chemotherapy and approved targeted therapies are ineffective for the patients.Or patients cannot tolerate current chemotherapy.
Exclusion Criteria:
- Active other disease and cannot control after treatment.
- Patients with actively infection of Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).
- Severe psychiatric disorder or other disease in central nervous system.
- Patients are infected with fungus,bacteria or virus,and are difficult to control after treatment.
- Patients with infection of HIV .
- Pregnant or lactating women.
- Patients who have Graft-Versus-Host Disease (GVHD) should receive systemic administration of immunosuppressive agents.
- Patients have received other genetic therapy products.
- Patients who have received systemic administration of glucocorticoid agents in one week before CART therapy.
- Any situation may do harm to the subjects or interfere the results.
- Have had Prolonged QT interval or severe heart disease in the past.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CART therapy in Acute myeloid leukemia
In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia(AML)patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
|
one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events that Are related to treatment
Time Frame: 2 years
|
Determine the toxicity profile of the CD38/CD33/CD56/CD123/CD117/CD133/CD34/ Mucl-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate 2 year overall survival(OS) after infusion of CD38/CD33/CD56/CD123/ CD117/CD133/CD34/Mucl-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year overall survival(OS) after CD38/CD33/CD56/CD123/CD117/CD133/ CD34/Mucl-CART infusion and sequential treatment with Relapsed/Refractory AML
|
2 years
|
Estimate 2 year relapse rate after infusion of CD38/CD33/CD56/CD123/CD117/CD133/ CD34/Mucl-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year relapse rate after CD38/CD33/CD56/CD123/CD117/CD133/CD34/ Mucl-CART infusion and sequential treatment with Relapsed/Refractory AML
|
2 years
|
Estimate 2 year progression free survival after CD117/CD133/CD34/ Mucl-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year progression free survival after CD38/CD33/CD56/CD123/CD117/ CD133/CD34/Mucl-CART infusion and sequential treatment with Relapsed/Refractory AML
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yanjie He, Zhujiang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-XYNK-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Acute Myeloid Leukemia(AML)
-
AvenCell Europe GmbHGCP-Service International Ltd. & Co. KGTerminatedAcute Myeloid Leukemia | Relapsed AML | Refractory AMLGermany
-
Elucida OncologyTherapeutic Advances in Childhood Leukemia and Lymphoma (TACL)WithdrawnAcute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
AstraZenecaTerminatedRelapsed or Refractory Acute Myeloid Leukemia (AML)United States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingTreatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)China
-
New Epsilon Innovation LimitedActive, not recruitingAdvanced Solid Tumor | Relapsed AML | Refractory AMLHong Kong
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
Arog Pharmaceuticals, Inc.CompletedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States
Clinical Trials on CART therapy in Acute myeloid leukemia(AML)
-
GlaxoSmithKlineNot yet recruitingNeoplasms, Head and NeckUnited States, Taiwan, Mexico, Belgium, Sweden, Australia, Germany, Canada, Japan, Norway, Portugal, Turkey, United Kingdom, Korea, Republic of, Argentina, Italy, Poland, Romania, Czechia, Hungary, Brazil, France, Greece
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
University of California, Los AngelesRecruitingCardiovascular Diseases | Atherosclerosis | Arterial Occlusion | HematomaUnited States
-
University of California, Los AngelesCompletedCardiovascular Diseases | Arterial Occlusion | HematomaUnited States
-
Assiut UniversityUnknownAdult Acute Myeloid Leukemia
-
GlaxoSmithKlineActive, not recruitingLung Cancer, Non-Small CellArgentina, Korea, Republic of, Spain, Finland, Taiwan, Italy, Netherlands, Germany, Australia, Mexico, United States, Belgium, Canada, United Kingdom, Greece, Romania, Sweden, Russian Federation, Poland, France, Brazil, Japan, Thailand and more
-
Grupo Español de Tratamiento de Tumores de Cabeza...GlaxoSmithKline; MFARRecruitingHead and Neck Squamous Cell CarcinomaSpain
-
GlaxoSmithKlineiTeos TherapeuticsRecruitingLung Cancer, Non-Small CellFinland, Italy, Netherlands, Spain, United States, Argentina, Belgium, Brazil, Germany, Greece, Hungary, Korea, Republic of, United Kingdom, Poland, France, Thailand, Japan, South Africa, Turkey, United Arab Emirates, Mexico, Port...
-
Ludwig-Maximilians - University of MunichCompleted